

**Oxford BioDynamics**  
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

**OBD's Oxford Lab accredited by UKAS to run EpiSwitch® Clinical Tests in the UK**

- OBD's facility in Oxford has been accredited by UKAS as clinical lab under the ISO 15189 standard
- Clinical validation of EpiSwitch CiRT has been completed in the Oxford lab, further improving the test result turnaround time
- All orders for both CiRT and PSE in the UK and Europe will be processed within the UK lab

**Oxford, UK - 9 May 2025** -Oxford BioDynamics Plc (AIM: OBD) a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces that its UK facility in Oxford has been accredited by the United Kingdom Accreditation Service (UKAS) as a clinical laboratory under the ISO 15189 standard.

The Company is also pleased to confirm the successful completed validation of its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) as a clinical test in this UK laboratory. CiRT is OBD's best-in-class stratification tool that empowers clinicians to identify which patients are likely to respond to a widely used class of immunotherapies: immune checkpoint inhibitors. The CiRT blood test is already available in the UK, but up to now, testing was performed in OBD's US CLIA-certified facility.

Thomas Guiel, Chief Operating Officer of OBD, said:

*"The immediate benefit for cancer patients seeking a CiRT test in the UK will be the significant reduction in the elapsed time from receipt of an order to result, which will now be 3-5 days. UKAS accreditation of our clinical lab in the UK under ISO15189 is a significant milestone that underscores our dedication to delivering high-quality and timely diagnostic testing to support healthcare providers and patients in the UK and Europe, meeting the stringent ISO requirements for patient testing and data security."*

The successful validation of CiRT in the UK is an important advance for OBD's British partners and customers, including its strategic partner, Bupa UK<sup>1</sup>.

This milestone completes OBD's strategy to implement clinical testing operations at its UK base, commissioned in April 2024.

More information on CiRT may be found at [www.myCiRT.com](http://www.myCiRT.com).

- Ends -

**References**

1: Oxford BioDynamics Plc. (Oct 2023). Bupa UK to cover EpiSwitch® CiRT for customers.  
[https://otp.tools.investis.com/clients/uk/oxford\\_biodynamics\\_plc/rns/regulatory-story.aspx?cid=2040&newsid=1726458](https://otp.tools.investis.com/clients/uk/oxford_biodynamics_plc/rns/regulatory-story.aspx?cid=2040&newsid=1726458)

**For more information:**

<b>Oxford BioDynamics PLC</b>	+44 (0)1865 518910
Iain Ross Executive Chairman	
Paul Stockdale, CFO	

<b>Shore Capital - Nominated Adviser and Broker</b>	+44 (0)20 7408 4090
Advisory: Stephane Auton / Lucy Bowden	
Broking: Fiona Conroy	

<b>WG Partners - Joint Broker</b>	+44 (0)20 3705 9330
David Wilson / Claes Spång / Satheesh Nadarajah /	
Erland Sternby	

<b>OAK Securities - Joint Broker</b>	+44 (0)20 3973 3678
Jerry Keen / Henry Clarke / Damion Carruel	

<b>Camarco - Financial PR</b>	+44 (0)20 3757 4980
Marc Cohen / Tilly Butcher / Fergus Young	OBDFinancial@camarco.co.uk

**Notes for Editors**

**About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Cancer Detection Test) and [EpiSwitch® CiRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com), X (@OxBioDynamics) or [LinkedIn](#).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRASSIESAEISEEI